Table 2.
Clinical benefit rate and best overall response in 20 evaluable patients
| n = 20 | Week 8 | Week 16 | Week 24 | Week 32 | Week 40 | Week 48 | Week 56 |
|---|---|---|---|---|---|---|---|
| Clinical benefit rate, overall response, n (%) RECIST v.1.1 | |||||||
| Stable disease | 11 | 5 | 2 | 2 | 2 | 1 | 1 |
| Progressive disease | 9 | 15 | 18 | 18 | 18 | 19 | 19 |
| Clinical benefit rate (CBR) | 55% | 25% | 10% | 10% | 10% | 5% | 5% |
| Best overall response (n=20) | |||||||
| Gastric cancer, n=2 | 1 SD | 1 SD | 1 SD | 1 SD | 1 SD | 1 SD | 1 SD |
| Anal cancer, n=1 | 1 SD | 1 SD | 1 SD | 1 SD | 1 SD | 0 | 0 |
| Colorectal cancer, n=5 | 3 SD | 1 SD | 0 | 0 | 0 | 0 | 0 |
| Lung cancer, n=5 | 3 SD | 1 SD | 0 | 0 | 0 | 0 | 0 |
| Cervical cancer, n=1 | 1 SD | 1 SD | 0 | 0 | 0 | 0 | 0 |
| Ovarian cancer, n=1 | 1 SD | 0 | 0 | 0 | 0 | 0 | 0 |
| Renal cancer, n=1 | 1 SD | 0 | 0 | 0 | 0 | 0 | 0 |
| Breast cancer, n=2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fallopian tube cancer, n=1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pancreas cancer, n=1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |